New EU Filings Include First Self-Administered Treatment For Myasthenia Gravis

UCB’s zilucoplan for treating gMG is among the latest new drugs that the European Medicines Agency has started reviewing for potential EU marketing approval.

Close up shot of team of professionals meeting with digital tablet and charts. Business people discussing financial plan. Human hands pointing at grap
The EMA has started reviewing a new batch of drug marketing applications • Source: Alamy

Zilucoplan, UCB’s investigational treatment for generalized myasthenia gravis (gMG) in adults, is among the latest drugs that the European Medicines Agency has added to its list of products under review for potential pan-EU marketing authorization.

Zilucoplan, which is not yet authorized anywhere in the world, is a once-daily self-administered subcutaneous peptide inhibitor of complement component...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet